769158-12-5

Basic information

• Product Name: 2-CHLORO-6-FLUOROQUINAZOLIN-4(3H)-ONE
• Synonyms: 2-CHLORO-6-FLUOROQUINAZOLIN-4(3H)-ONE;2-chloro-6-fluoroquinazolin-;4(3H)-Quinazolinone, 2-chloro-6-fluoro-;2-Chloro-6-fluoro-4(1H)-quinazolinone;2-chloro-6-fluoroquinazolin-4-ol;2-chloro-6-fluoro-4(3H)-Quinazolinone
• CAS NO: 769158-12-5
• Molecular Formula: C₈H₄ClFN₂O
• Molecular Weight: 198.59
• Mol File: 769158-12-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 339.8 °C at 760 mmHg
• Flash Point: 159.3 °C
• Appearance: /
• Density: 1.61±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 9E-05mmHg at 25°C
• Refractive Index: 1.664
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-CHLORO-6-FLUOROQUINAZOLIN-4(3H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-6-FLUOROQUINAZOLIN-4(3H)-ONE(769158-12-5)
• EPA Substance Registry System: 2-CHLORO-6-FLUOROQUINAZOLIN-4(3H)-ONE(769158-12-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 769158-12-5(Hazardous Substances Data)

Usage

General Description

2-CHLORO-6-FLUOROQUINAZOLIN-4(3H)-ONE is a chemical compound with the molecular formula C8H4ClFN2O. It is a quinazoline derivative that contains a chloro and a fluoro group attached to the quinazolin-4-one ring. 2-CHLORO-6-FLUOROQUINAZOLIN-4(3H)-ONE has potential applications in the pharmaceutical industry, particularly in the development of new drugs for various medical conditions. It may also be used as a building block in organic synthesis for the creation of other chemical compounds. Additionally, 2-CHLORO-6-FLUOROQUINAZOLIN-4(3H)-ONE may have various biological and pharmacological properties that could be studied for potential therapeutic benefits.

InChI:InChI=1/C8H4ClFN2O/c9-8-11-6-2-1-4(10)3-5(6)7(13)12-8/h1-3H,(H,11,12,13)

Upstream product

• 134517-57-0 2,4-dichloro-6-fluoro-quinazoline 
• 446-08-2 2-amino-5-fluorobenzoic acid 
• 88145-90-8 6-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazoline 

Downstream Products

• 769158-13-6 2-((2-chloro-6-fluoro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 
• 1250263-97-8 2-[{(1R,2R)-2-(dimethylamino)cyclohexyl}amino]-6-fluoroquinazolin-4(1H)-one 

Relevant articles and documents

PIPERAZINE DERIVATIVES AS MAGL INHIBITORS

The invention provides new heterocyclic compounds having general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Substituted piperazine compounds, application method and applications thereof

The invention discloses substituted piperazine compounds, an application method and applications thereof. Specifically, the invention relates to piperazine compounds and pharmaceutical compositions thereof for inhibiting reuptake of 5-hydroxytryptamine and/or stimulation of 5-HT1A acceptor. The invention also relates to a preparation method of the compounds and pharmaceutical compositions thereof, and an application of the compounds and pharmaceutical compositions thereof in the treatment of central nervous system dysfunction.

Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase 111 trials in patients with type 2 diabetes.